Marksans Pharma Ltd.
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 28.7%
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (₹ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (₹ Crores, last 1 year)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | ₹1.17 K Cr | — | ₹188.00 Cr | — | — | 13.6% | 37.6% | 40.3% |
Showing the latest year only. Sign up free for the full history.
Financial Statements
Income statement, balance sheet, and cash flow (₹ Crores, as reported)
Showing the latest year only. Sign up free for the full history.
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,251 |
| Total Expenses | 998 |
| EBIT / Operating Profit | 254 |
| OPM % | 20% |
| Other Income | 89 |
| Finance Costs | 1 |
| Depreciation & Amortisation | 32 |
| Profit Before Tax | 310 |
| Tax % | - |
| Net Profit / PAT | 241 |
| EPS (₹) | 5.31 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Marksans Pharma Ltd.this co. | ₹7.87 K Cr | ₹1.17 K Cr | 32.70 | 5.27 | 38.07 | 37.6% |
| Sun Pharmaceutical Industries Ltd. | ₹4.15 L Cr | ₹23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | ₹1.71 L Cr | ₹9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | ₹1.33 L Cr | ₹9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | ₹1.17 L Cr | ₹19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | ₹1.05 L Cr | ₹8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | ₹1.00 L Cr | ₹2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | — | ₹3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |